Prediction of Survival in Multiple Myeloma Based on Gene Expression Profiles Reveals Cell Cycle and Chromosomal Instability Signatures in High-Risk Patients and Hyperdiploid Signatures in Low-Risk Patients: A Study of the Intergroupe Francophone du M
about
Prognostic significance of copy-number alterations in multiple myelomaMolecular Classification and Pharmacogenetics of Primary Plasma Cell Leukemia: An Initial Approach toward Precision MedicineMany multiple myelomas: making more of the molecular mayhemMolecular pathogenesis of multiple myeloma: basic and clinical updatesDrug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms.Evaluating gene expression profiling by quantitative polymerase chain reaction to develop a clinically feasible test for outcome prediction in multiple myelomaMicroenvironmental influence on pre-clinical activity of polo-like kinase inhibition in multiple myeloma: implications for clinical translationInhibition of DEPDC1A, a bad prognostic marker in multiple myeloma, delays growth and induces mature plasma cell markers in malignant plasma cellsProof of the concept to use a malignant B cell line drug screen strategy for identification and weight of melphalan resistance genes in multiple myelomaDevelopment of a Drug-Response Modeling Framework to Identify Cell Line Derived Translational Biomarkers That Can Predict Treatment Outcome to Erlotinib or SorafenibPrimary plasma cell leukemia 2.0: advances in biology and clinical management.Advances in understanding prognosis in myeloma.Impact of high-risk classification by FISH: an eastern cooperative oncology group (ECOG) study E4A03.Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project.Semiparametric transformation models for semicompeting survival data.Translating a gene expression signature for multiple myeloma prognosis into a robust high-throughput assay for clinical use.Homozygous deletion mapping in myeloma samples identifies genes and an expression signature relevant to pathogenesis and outcomeA DNA repair pathway score predicts survival in human multiple myeloma: the potential for therapeutic strategyThe dChip survival analysis module for microarray data.Implications of heterogeneity in multiple myeloma.Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma.Gene expression profile alone is inadequate in predicting complete response in multiple myeloma.Assessment of performance of survival prediction models for cancer prognosisIdentification of pluripotent and adult stem cell genes unrelated to cell cycle and associated with poor prognosis in multiple myeloma.Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma.Assessment of reproducibility of cancer survival risk predictions across medical centersDisruption of Src function potentiates Chk1-inhibitor-induced apoptosis in human multiple myeloma cells in vitro and in vivo.A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell linesNew insights, recent advances, and current challenges in the biological treatment of multiple myeloma.Preclinical efficacy of sepantronium bromide (YM155) in multiple myeloma is conferred by down regulation of Mcl-1.A novel measure of chromosome instability can account for prognostic difference in multiple myeloma.Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitorsGenetics of multiple myeloma: another heterogeneity level?HDAC4, a prognostic and chromosomal instability marker, refines the predictive value of MGMT promoter methylation.Impact of genetic abnormalities after allogeneic stem cell transplantation in multiple myeloma: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire.Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasoneRemoving batch effects from purified plasma cell gene expression microarrays with modified ComBat.A gene expression based predictor for high risk myeloma treated with intensive therapy and autologous stem cell rescue.Profound impact of sample processing delay on gene expression of multiple myeloma plasma cells.Niche-Based Screening in Multiple Myeloma Identifies a Kinesin-5 Inhibitor with Improved Selectivity over Hematopoietic Progenitors.
P2860
Q24643402-D0BE8274-7C4B-4D09-B36B-1F247FF30220Q26799238-0B61698D-FB13-4756-9728-5418BE27E7D8Q26852892-33461DBF-B001-4966-A1C0-4F6463C2A60AQ27026205-73FE1EF4-8793-4163-8C6E-122E6C58FE61Q27692033-4DBEEB7A-E89D-422F-9C9B-DB737C42A86DQ28296718-FEF73353-D5D7-4D11-8247-894D0FA93E4BQ28478937-02D05784-14D7-4F54-8B21-5186A35514C2Q28487347-BDF363D4-5F8C-489F-8A89-96B0B37E6B0FQ28537857-987864D5-32F2-4896-9DAD-EFCE7440C90FQ28548663-A3958C3D-0D7F-43F4-8562-F5A191CD88BEQ30243927-FFD6FFAF-A2F1-48D5-BF4B-0F67802C6F03Q30244061-D8CF008F-30CE-411E-9B0B-9327B5DB1A7CQ30424188-84131F12-AA58-4B24-BE2A-6CE1BE37AA43Q30571858-9ACFBDE6-7BAF-414A-831F-87F8388201D5Q30805024-4570BA68-FF7D-48D6-BEBA-F8ED80556193Q33655234-B7D0856E-6A90-48A2-8759-F63F58CD2B77Q33737846-E67952CD-5606-4B1A-84DA-FC4386727EB7Q33757020-D327BF85-D50A-45D1-A18A-0CB713659746Q33841474-5CCF8622-6422-4547-B1CF-781C578E59AFQ33914824-C545B8F9-D300-4E0A-B5AC-8FFE2C6125B7Q34173892-4F2336D3-001A-4C0C-BCEC-ABBE8C702191Q34345502-500814BA-2763-4D9A-AC5F-F43F39E9F73FQ34348386-BBFA5689-549C-46DD-9585-729CC7251B00Q34364560-619A018C-D487-4F7D-A04C-9CBA8F6DECD1Q34451553-7591EE89-6501-4B81-B031-248531824DF4Q34593019-49709C8A-4BAA-472B-A52D-8A1F331E4F35Q34667764-57B417AE-668F-44F8-B7FD-48B27C82FD7FQ34750568-7EC932C1-94A9-4B88-B3B4-9354465CCFB0Q34773850-BBCA3395-A18A-435F-A1A9-9E9E4ACA2418Q34786411-0F6151F1-9BC7-4A29-89C1-CD979B817EC4Q34805291-877B0488-D024-47C3-8CBB-3472B2B2B1F7Q35142790-1DBB5FA9-E9AF-48E4-B67F-BEE9BCE8AA1EQ35197437-86F081D2-E97B-45C1-9710-D60FBE4485C5Q35203538-F1AA9999-C352-4F08-A09C-0118E51A2567Q35265979-F50087F0-AD6D-40F4-A010-AC2F3338BDCCQ35485758-A35B0F77-871D-40DE-A0DA-728A0C6D03CEQ35607341-17BD4DEC-24C7-4F22-8936-3ACA885EDFBEQ35651050-A1942707-D721-42C3-92F0-377A46DAE1B3Q35881063-BB892286-A349-41EF-BF46-329531CE8B81Q35915829-DA45BF50-CE51-46C3-9D45-6975EEF1FC83
P2860
Prediction of Survival in Multiple Myeloma Based on Gene Expression Profiles Reveals Cell Cycle and Chromosomal Instability Signatures in High-Risk Patients and Hyperdiploid Signatures in Low-Risk Patients: A Study of the Intergroupe Francophone du M
description
article
@en
im Oktober 2008 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в жовтні 2008
@uk
name
Prediction of Survival in Mult ...... e Intergroupe Francophone du M
@en
Prediction of Survival in Mult ...... e Intergroupe Francophone du M
@nl
type
label
Prediction of Survival in Mult ...... e Intergroupe Francophone du M
@en
Prediction of Survival in Mult ...... e Intergroupe Francophone du M
@nl
prefLabel
Prediction of Survival in Mult ...... e Intergroupe Francophone du M
@en
Prediction of Survival in Mult ...... e Intergroupe Francophone du M
@nl
P2093
P50
P356
P1476
Prediction of survival in mult ...... rgroupe Francophone du Myélome
@en
P2093
Catherine Charbonnel
Florence Magrangeas
Intergroupe Francophone du Myélome
Jean-Luc Harousseau
Laurence Lodé
Michel Attal
Olivier Decaux
Pascal Jézéquel
Régis Bataille
Stéphane Minvielle
P304
P356
10.1200/JCO.2007.13.8545
P407
P577
2008-06-30T00:00:00Z